Advertisement

Drugs & Therapy Perspectives

, Volume 13, Issue 5, pp 13–16 | Cite as

Is abciximab worth the cost?

Drug Economics and Quality of Life
  • 9 Downloads

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Foster RH, Wiseman LR. Abciximab: an updated review of its use in ischaemic heart disease. Drugs 1998 Oct; 56(4): 629–65PubMedCrossRefGoogle Scholar
  2. 2.
    Mark DM, Talley JD, Topol EJ, et al. Economic assessment of platelet glycoprotein IIb/IIIa inhibition for prevention of ischemic complications of high-risk coronary angioplasty. Circulation 1996 Aug 15; 94: 629–35PubMedCrossRefGoogle Scholar
  3. 3.
    EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 1994 April 7; 330(14): 956–61CrossRefGoogle Scholar
  4. 4.
    Topol EJ, Califf RM, Weisman HF, et al. Randomised trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: results at six months. Lancet 1994 Apr 9; 343: 881–6PubMedCrossRefGoogle Scholar
  5. 5.
    Aristides M, Gliksman M, Rajan N, et al. Effectiveness and cost effectiveness of single bolus treatment with abciximab (Reo Pro) in preventing restenosis following percutaneous transluminal coronary angioplasty in high-risk patients. Heart 1998 Jan; 79: 12–7PubMedGoogle Scholar
  6. 6.
    Sacristán JA, Navarro O, Huete T, et al. Cost-effectiveness of the monoclonal antibody c7E3 in high risk coronary angioplasty in Spain. Br J Med Econ 1996; 10: 169–83Google Scholar
  7. 7.
    van Hout BA, Simoons ML. Costs and effects of c7E3 in high risk PTCA patients. An indirect analysis for The Netherlands. Eur Heart J 1995 Nov; 16 Suppl L: 81–5PubMedGoogle Scholar
  8. 8.
    Oh PI, Pritchard-Oh L, Cohen EA. Cost-effectiveness analysis of abciximab used in PTCA from a Canadian hospital perspective [abstract]. Can J Cardiol 1997 Sep; 13 Suppl. C: 104Google Scholar
  9. 9.
    Zed PJ, Frighetto L, Sunderji R, et al. Cost-effectiveness analysis of abciximab: a Canadian hospital perspective. Ann Pharmacother 1998 May; 32: 536–42PubMedCrossRefGoogle Scholar
  10. 10.
    van Hout BA, Bowman L, Zelinger DJ, et al. Costs and effects of therapy for acute coronary syndromes: the case of abciximab in high risk patients undergoing percutaneous transluminal coronary angioplasty in the EPIC study. Am Heart J 1998 Apr; 135(4): S98–106PubMedCrossRefGoogle Scholar
  11. 11.
    CAPTURE Investigators. Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE study. Lancet 1997 May 17; 349: 1429–35CrossRefGoogle Scholar
  12. 12.
    Brener SJ, Ellis SG, DeLuca SA, et al. Abciximab in coronary angioplasty — comparison of planned and rescue administration [abstract]. J Invasive Cardiol 1997; 9 Suppl. C: 50CGoogle Scholar
  13. 13.
    Abernathy GB, Hewitt KK. Costs and outcomes analysis of abciximab use in a community teaching hospital. Am J Health Syst Pharm 1998 Dec 15; 55 Suppl. 4: S35–S37PubMedGoogle Scholar

Copyright information

© Adis lnternational Limited 1999

Personalised recommendations